About
I obtained a B.S. in Chemistry from the University of Illinois in Urbana/Champaign and a…
Activity
-
Excited to announce Pfizer's partnership with Triana Biomedicines! Looking forward to a productive partnership to impact patient lives. Thanks to…
Excited to announce Pfizer's partnership with Triana Biomedicines! Looking forward to a productive partnership to impact patient lives. Thanks to…
Liked by Chris O'Donnell
-
Big news today for TRIANA! Announcing a research collaboration with Pfizer to Discover novel molecular glue degraders https://lnkd.in/exAGkn68
Big news today for TRIANA! Announcing a research collaboration with Pfizer to Discover novel molecular glue degraders https://lnkd.in/exAGkn68
Liked by Chris O'Donnell
-
I am honored and humbled to share the most exciting news on today's FDA approval of Vorasidenib. https://lnkd.in/eXXXrye5 I am so grateful to having…
I am honored and humbled to share the most exciting news on today's FDA approval of Vorasidenib. https://lnkd.in/eXXXrye5 I am so grateful to having…
Liked by Chris O'Donnell
Experience & Education
-
Arrakis Therapeutics
View Chris’s full experience
See their title, tenure and more.
or
Publications
-
A facile synthesis of 2,3-azaisoindoline
Tetrahedron Lett. 2010, 51 (45), 5859-5860
See publicationhttps://doi.org/10.1016/j.tetlet.2010.08.091
-
A General Route to the Synthesis of 1,5-Methano- and 1,5-Ethano-2,3,4,5-tetrahydro-1H-3-benzazepines
J. Org. Chem. 2004, 69, 5756
See publicationDOI: 10.1021/jo049122q
-
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions
Sci. Transl. Med. 2017, eaag2611
See publicationDOI: 10.1126/scitranslmed.aag2611
-
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active gamma-secretase inhibitor
J. Med. Chem. 2012, 55 (7), 3414-24
See publicationDOI: 10.1021/jm300094u
-
Aza-Cope Rearrangement-Mannich Cyclizations for the Formation of Complex Tricyclic Amines: Stereocontrolled Total Synthesis of ()-Gelsemine
J. Am. Chem. Soc. 2005, 127, 18046
See publicationDOI: 10.1021/ja055710p
-
Biosynthetic engineering and fermentation media development leads to gram-scale production of spliceostatin natural products in Burkholderia sp.
Metab. Eng. 2016, 33, 67-75
See publicationhttps://doi.org/10.1016/j.ymben.2015.11.003
-
Cyclic Hydropyran Oligolides as Preorganized Ligand Arrays: Cumulative Effects of Structural Elements on Shape and Cation Binding
J. Am. Chem. Soc. 1995, 117, 12649
See publicationDOI: 10.1021/ja00155a035
-
Cytotoxic spliceostatins from Burkholderia sp. and their semisynthetic analogs
Nat. Prod. 2014, 77 (8), 1864-1870
See publicationDOI: 10.1021/np500342m
-
Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators
Bioorg. Med. Chem. Lett. 2012, 22 (8), 2906-2911
See publicationhttps://doi.org/10.1016/j.bmcl.2012.02.059
-
Design of Pyridopyrazine-1,6-dione γ-Secretase Modulators that Align Potency, MDR Efflux Ratio, and Metabolic Stability
ACS Medicinal Chemistry Letters 2015, 6 (5), 596-601
See publicationDOI: 10.1021/acsmedchemlett.5b00070
-
Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads.
ACS Medicinal Chemistry Letters 2016, 7, 999-1004
-
Design, Synthesis, and Pharmacological Evaluation of a Novel Series of Pyridopyrazine-1,6-dione γ-Secretase Modulators
J. Med. Chem. 2014, 57 (3), 1046-1062
See publicationDOI: 10.1021/jm401782h
-
Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists
Bioorg. Med. Chem. Lett. 2011, 21 (2), 865-8
See publicationhttps://doi.org/10.1016/j.bmcl.2010.11.066
-
Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates
Bioconjugate Chem. 2016, 27 (4), 1030-1039
See publicationDOI: 10.1021/acs.bioconjchem.6b00054
-
Discovery and Characterization of a Novel Dihydroisoxazole Class of α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) Receptor Potentiators
J. Med. Chem. 2013, 56 (22), 9180-9191
See publicationDOI: 10.1021/jm401274b
-
Discovery of 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in vivo Efficacy
J. Med. Chem. 2010, 53, 1222-1237
See publicationDOI: 10.1021/jm9015075
-
Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications
J. Med. Chem. 2014, 57 (24), 10527-43
See publicationDOI: 10.1021/jm501649k
-
High-throughput screening in embryonic stem cell-derived neurons identifies potentiators of alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate-type glutamate receptors
J. Biol. Chem. 2010, 285 (22), 17209-17
See publicationdoi:10.1074/jbc.M109.098814
-
Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate
J. Med. Chem. 2018, 61 (3), 1001-1018
See publicationDOI: 10.1021/acs.jmedchem.7b01466
-
Identification of α7 nicotinic acetylcholine receptor agonists for their assessment in improving cognition in schizophrenia
RSC Drug Discovery Ser. 2011, 4 (Accounts in Drug Discovery), 332-362
See publicationhttp://dx.doi.org/10.1039/9781849731980-00332
-
Investigational antibody drug conjugates for solid tumors
Expert Opin. Invest. Drugs 2011, 20, 1131-1149
See publicationhttps://doi-org.proxy1.athensams.net/10.1517/13543784.2011.582866
-
Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates
Chem. Biol. 2013, 20 (2), 161-7
See publicationhttps://doi.org/10.1016/j.chembiol.2013.01.010
-
Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells
Mol Cancer Ther 2013, 12 (1), 38-47
See publicationDOI: 10.1158/1535-7163.MCT-12-0603
-
Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as γ-Secretase Inhibitors
J. Med. Chem. 2011, 54, 7772-7783
See publicationDOI: 10.1021/jm200893p
-
Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design
Mol. Cancer Ther. 2016, 15 (5), 958-970
See publicationDOI: 10.1158/1535-7163.MCT-15-1004
-
Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate.
PLoS One 2017, 12 (5), e0178452/1-e0178452/16
-
Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads
Bioconjugate Chem. 2016, 27 (8), 1880-1888
See publicationDOI: 10.1021/acs.bioconjchem.6b00291
-
New cytotoxic benzosuberene analogs. Synthesis, molecular modeling and biological evaluation
Bioorg. Med. Chem. Lett. 2013, 23 (24), 6688-6694
See publicationhttps://doi.org/10.1016/j.bmcl.2013.10.039
-
Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
Mol. Cancer Ther. 2015, 14 (8), 1868-1876
See publicationDOI: 10.1158/1535-7163.MCT-15-0188
-
Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism
ACS Medicinal Chemistry Letters 2016, 7, 977-982
See publicationDOI: 10.1021/acsmedchemlett.6b00195
-
RN927C, a site-specific trop-2 antibody-drug conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models
Mol. Cancer Ther. 2016, 15 (11), 2698-2708.
-
Selective Mesylation of Vicinal Diols: A Systematic Case Study
J. Org. Chem. 1998, 63, 8614
See publicationDOI: 10.1021/jo981532p
-
Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates
AAPS Journal 2017, 19 (4), 1123-1135
-
Spliceostatin hemiketal biosynthesis in Burkholderia spp. is catalyzed by an iron/α-ketoglutarate-dependent dioxygenase
Proc. Natl. Acad. Sci. U. S. A. 2014, 111 (33), E3376-E3385
See publicationhttps://doi.org/10.1073/pnas.1408300111
-
Synthesis and SAR studies of 1,4-diazabicyclo[3.2.2]nonane phenyl carbamates - subtype selective, high affinity α7 nicotinic acetylcholine receptor agonists
Bioorg. Med. Chem. Lett. 2009, 19 (16), 4747-4751
See publicationhttps://doi.org/10.1016/j.bmcl.2009.06.059
-
Synthesis of 3-methoxy-9-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5H-benzo[7]annulen-4-ol, a potent antineoplastic benzosuberene derivative for anti-cancer chemotherapy
Tetrahedron Lett. 2012, 53 (1), 64-66
See publicationhttps://doi.org/10.1016/j.tetlet.2011.10.145
-
Synthesis of Cyclic Hydropyran Oligolides with Convergent Amine, Amide, Phosphonate and Furan Appendages
Tetrahedron Lett. 1997, 38, 2593
See publicationhttps://doi.org/10.1016/S0040-4039(97)00422-X
-
Synthetic Approaches to the 2007 New Drugs
Mini Rev. Med. Chem. 2008, 8, 1526-48
See publicationDOI: 10.2174/138955708786786435
-
Synthetic approaches to the 2008 new drugs
Mini-Rev. Med. Chem. 2009, 9 (14), 1655-1675
See publicationDOI: 10.2174/138955709791012201
-
Synthetic approaches to the 2009 new drugs
Bioorg. Med. Chem. 2011, 19 (3), 1136-1154
See publicationhttps://doi.org/10.1016/j.bmc.2010.12.038
-
Synthetic approaches to the 2010 new drugs
Bioorg. Med. Chem. 2012, 20 (3), 1155-1174
See publicationhttps://doi.org/10.1016/j.bmc.2011.12.049
-
Synthetic approaches to the 2011 new drugs
Bioorg. Med. Chem. 2013, 21 (11), 2795-2825
See publicationhttps://doi.org/10.1016/j.bmc.2013.02.061
-
Synthetic approaches to the 2012 new drugs
Bioorg. Med. Chem. 2014, 22 (7), 2005-2032
See publicationhttps://doi.org/10.1016/j.bmc.2014.02.017
-
Synthetic approaches to the 2013 new drugs
Bioorg. Med. Chem. 2015, 23 (9), 1895-1922
See publicationhttps://doi.org/10.1016/j.bmc.2015.02.056
-
Synthetic approaches to the 2014 new drugs
Bioorg. Med. Chem. 2016, 24 (9), 1937-1980
See publicationhttps://doi.org/10.1016/j.bmc.2016.03.004
-
Synthetic Approaches to the New Drugs Approved During 2015
J. Med. Chem. 2017, 60 (15), 6480-6515
See publicationDOI: 10.1021/acs.jmedchem.7b00010
-
Synthetic Approaches to the New Drugs Approved During 2015
J. Med. Chem. 2017, 60 (15), 6480-6515
See publicationDOI: 10.1021/acs.jmedchem.7b00010
-
Template Macrolactonization of Trichloroethyl Ester Derivatives Catalyzed by Potassium Salts
J. Org. Chem. 1998, 63, 2715
See publicationDOI: 10.1021/jo970942v
-
The Discovery and Characterization of the α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Potentiator N-{(3S,4S)-4-[4-(5-Cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242)
J. Med. Chem. 2015, 58 (10), 4291-4308
See publicationDOI: 10.1021/acs.jmedchem.5b00300
-
Thiophosgene
Encyclopedia of Reagents for Organic Synthesis, Leo A. Paquette, Ed.; Wiley, V7, p4881-3
See publicationDOI: 10.1002/047084289X.rt103
-
Total Synthesis of ()-Gelsemine
Angew. Chem., Int. Ed. Eng. 1999, 38, 2934
See publicationDOI: 10.1002/(SICI)1521-3773(19991004)38:19<2934::AID-ANIE2934>3.0.CO;2-L
-
Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
Mol. Cancer Ther. 2015, 14 (4), 952-963
See publicationDOI: 10.1158/1535-7163.MCT-14-0862
-
Use of the Intramolecular Heck Reaction for Forming Congested Quaternary Carbon Stereocenters. Stereocontrolled Total Synthesis of ()-Gelsemine
J. Am. Chem. Soc. 2005, 127, 18054
See publicationDOI: 10.1021/ja055711h
More activity by Chris
-
Great to see #STORMTherapeutics featured in Labiotech.eu's summary of 'Six epigenetics companies making strides in 2024', highlighting STORM's…
Great to see #STORMTherapeutics featured in Labiotech.eu's summary of 'Six epigenetics companies making strides in 2024', highlighting STORM's…
Liked by Chris O'Donnell
-
We are delighted to share that #STORMTherapeutics is featured in the Medical Technology Magazine 'ASCO 2024 unveils practice - changing research in…
We are delighted to share that #STORMTherapeutics is featured in the Medical Technology Magazine 'ASCO 2024 unveils practice - changing research in…
Liked by Chris O'Donnell
-
I think they are on to something good here! Great job to the team at Storm!!
I think they are on to something good here! Great job to the team at Storm!!
Shared by Chris O'Donnell
-
📰 News alert 📰 #STORM presented interim Phase 1 clinical data on its first-in-class lead product #STC15 at the American Society of Clinical…
📰 News alert 📰 #STORM presented interim Phase 1 clinical data on its first-in-class lead product #STC15 at the American Society of Clinical…
Liked by Chris O'Donnell
-
I am pleased to share the latest edition of the "Synthetic Approaches..." annual drug review is now out in J. Med. Chem. I remember reading this…
I am pleased to share the latest edition of the "Synthetic Approaches..." annual drug review is now out in J. Med. Chem. I remember reading this…
Liked by Chris O'Donnell
-
PFIZER MED DESIGN PUBLICATION: I've always loved the arrow push on a 1,3-dipolar cycloaddition, so I really couldn't resist this paper from our La…
PFIZER MED DESIGN PUBLICATION: I've always loved the arrow push on a 1,3-dipolar cycloaddition, so I really couldn't resist this paper from our La…
Liked by Chris O'Donnell
-
Who makes the world go round? These two do! Thanks for bringing your A-Game EVERY day. @Christine(Wenzel)Petersen @HeatherHamilton
Who makes the world go round? These two do! Thanks for bringing your A-Game EVERY day. @Christine(Wenzel)Petersen @HeatherHamilton
Liked by Chris O'Donnell
-
Congratulations Simon Kerry and Ali Tavassoli!
Congratulations Simon Kerry and Ali Tavassoli!
Liked by Chris O'Donnell
-
Delighted to have Curve Therapeutics join our portfolio companies and to be joining the Board of Directors. So looking forward to working with this…
Delighted to have Curve Therapeutics join our portfolio companies and to be joining the Board of Directors. So looking forward to working with this…
Liked by Chris O'Donnell
-
SKY-0515 is a small molecule RNA splicing modifier developed through our novel SKYSTAR® platform. Having successfully advanced through single…
SKY-0515 is a small molecule RNA splicing modifier developed through our novel SKYSTAR® platform. Having successfully advanced through single…
Liked by Chris O'Donnell
-
I'm a judge at this year's BWB Awards! Learn more about this year's awards and submit your free nomination towards 10 life science categories by…
I'm a judge at this year's BWB Awards! Learn more about this year's awards and submit your free nomination towards 10 life science categories by…
Liked by Chris O'Donnell
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Chris O'Donnell in United States
-
Chris O'Donnell
FORMER NIKE VP // STRATEGIC LEADERSHIP // MARKETPLACE // PRODUCT // PEOPLE
-
Chris O'Donnell
Chief Business Officer | FL97, Inc
-
Chris O'Donnell
Senior Business Intelligence Engineer at Amazon
-
Chris O'Donnell
329 others named Chris O'Donnell in United States are on LinkedIn
See others named Chris O'Donnell